Long-term treatment with VYVANSE, first prodrug stimulant, demonstrates significant efficacy in ADHD
...sity Hospitals Case Medical Center. "As the first prodrug stimulant, VYVANSE will provide a novel approach to the delivery of stimulant medication for the treatment of ADHD." Long-term Treatment with VYVANSE Yields Significant ADHD Symptom Improvement In the long-term open-label extension trial, patien...Lisdexamfetamine dimesylate in ADHD phase 3 data presented
...ffer the effectiveness of a stimulant with a novel prodrug formulation that is inactive until metabolized in the body." New River Pharmaceuticals designed lisdexamfetamine dimesylate as a new ADHD medication in which d-amphetamine is covalently linked to l-lysine, a naturally occurring amino acid. Designed...Abuse liability study results of lisdexamfetamine dimesylate (NRP104) presented at CPDD
...esigned lisdexamfetamine dimesylate as an inactive prodrug in which d-amphetamine is bonded to l-lysine, a naturally occurring amino acid. Lisdexamfetamine dimesylate remains inactive until converted and active d-amphetamine is gradually released. On January 31, 2005, New River signed a collaborative agree...